ticlopidine and Coronary Thrombosis studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.

Research Excerpts

Excerpt	Relevance	Reference
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."	9.24	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."	9.22	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."	9.22	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications."	9.19	Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014)
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics."	9.17	Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013)
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)."	9.16	Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."	9.15	Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."	9.15	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."	9.14	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."	9.14	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."	8.89	Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease."	8.84	Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007)
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement."	8.80	Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999)
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)."	7.88	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."	7.85	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."	7.81	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."	7.79	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."	7.76	Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."	7.75	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	7.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	7.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting."	7.70	Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."	7.70	Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."	7.70	Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."	7.69	Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	6.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."	5.36	Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."	5.35	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."	5.24	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents."	5.24	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017)
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."	5.24	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone."	5.24	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."	5.22	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel."	5.22	Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016)
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation."	5.22	6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016)
"Despite broad differences in clinical profiles and indications for percutaneous coronary intervention by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end points compared with clopidogrel without an excess in severe bleeding in both the US and non-US subgroups."	5.22	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."	5.22	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled."	5.20	High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015)
"The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin."	5.20	Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015)
"The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described."	5.19	Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014)
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications."	5.19	Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."	5.19	Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
"The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome."	5.17	Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). ( Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C, 2013)
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics."	5.17	Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013)
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)."	5.16	Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)."	5.15	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."	5.15	Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."	5.15	Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease."	5.14	Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."	5.14	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."	5.14	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
" The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding."	5.13	Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I ( Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD, 2008)
"In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone."	5.11	Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005)
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."	5.09	Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)
"Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding."	4.95	Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."	4.90	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."	4.89	Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
"P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization."	4.88	Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012)
"Clopidogrel has become part of the mainstay of therapy for acute coronary syndromes and in patients post stenting."	4.87	Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. ( Dart, AM; Fernando, H; Peter, K; Shaw, JA, 2011)
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease."	4.84	Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007)
"The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease."	4.84	[Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007)
"The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse."	4.84	Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007)
"The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists."	4.82	Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005)
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement."	4.80	Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999)
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)."	3.88	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018)
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES."	3.85	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017)
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding."	3.85	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."	3.85	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."	3.83	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."	3.81	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding."	3.81	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015)
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."	3.80	Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)
"The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available."	3.80	Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014)
"A 36 year-old man, who had undergone a paclitaxel-eluting stent deployment into the left main (LM) coronary artery three years before, was admitted after successful resuscitation following out-of-hospital cardiac arrest due to an acute ST-segment elevation myocardial infarction."	3.79	Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery. ( Janus, M; Lesiak, M; Lukawski, K; Prech, M, 2013)
" Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown."	3.79	Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013)
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation."	3.79	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."	3.79	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
" We examined the influence of previously described polymorphisms, related to aspirin and clopidogrel resistance, on treatment outcome in a real life unselected population of patients presenting with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention."	3.79	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. ( Boden, H; Guchelaar, HJ; Heijmans, BT; Jukema, JW; Putter, H; Schalij, MJ; Trompet, S; van der Hoeven, BL; Verschuren, JJ; Wessels, JA, 2013)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."	3.76	Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."	3.75	Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation."	3.75	Potential Interaction between clopidogrel and proton pump inhibitors. ( Howard, PA; Vacek, JL, 2009)
" We describe a case of very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment, which occurred just 2 weeks after its withdrawal, causing an acute coronary syndrome that was promptly resolved with an urgent invasive strategy."	3.74	Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. ( Bucciarelli-Ducci, C; Colantonio, R; Fedele, F; Mancone, M; Sangiorgi, GM; Sardella, G, 2007)
"We describe a case of an 81-year-old man with acute ST-elevation myocardial infarction (STEMI), who received a loading dose of clopidogrel (300 mg) and aspirin (ASA) (300 mg) prior to primary coronary intervention of critical left anterior descending coronary artery stenosis."	3.74	[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report]. ( Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M, 2007)
"To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)."	3.74	Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	3.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	3.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting."	3.70	Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."	3.70	Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."	3.70	Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."	3.69	Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."	2.79	Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."	2.79	Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."	2.78	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI."	2.77	Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012)
" (2) Clopidogrel may be under dosed in obese patients."	2.75	Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010)
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding."	2.75	Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010)
" Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel."	2.75	High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. ( Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	2.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Cilostazol is a potent antiplatelet agent with less serious side effects."	2.69	Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
"Ticlopidine-plus-aspirin has become standard antiplatelet therapy for the prevention of thrombotic complications after coronary stenting."	2.69	Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. ( Aguirre, FV; Ligon, RW; Lucore, CL; Mishkel, GJ; Rocha-Singh, KJ, 1999)
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."	2.69	A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)
"Ticlopidine therapy was discontinued in 1."	2.68	Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996)
"Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel."	2.53	Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)
"Clinical trials enrolling STEMI patients were identified and relevant data was extracted."	2.53	Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. ( Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY, 2016)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."	2.50	Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition."	2.44	Aspirin and clopidogrel resistance. ( Fitzgerald, DJ; Maree, A, 2007)
" This approach may be in the future influenced by further progress in drug-eluting stents development and by prospectively acquired information on long-term administration of clopidogrel to such patients."	2.44	[Late coronary stent thrombosis and clopidogrel]. ( Herman, A; Matejka, J; Varvarovský, I, 2007)
"Ticlopidine is an inhibitor of platelets function in vivo."	2.43	[Place of ticlopidine in antiplatelet treatment]. ( Goch, A; Goch, JH; Wlazłowski, R, 2005)
"We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis."	2.43	Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006)
"Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects."	2.40	The thienopyridines in coronary artery disease. ( Berger, PB, 1999)
"Major bleeding was a significant correlate of DAPT ANA within 6 months."	1.42	Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015)
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction."	1.40	Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014)
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization."	1.39	Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013)
"Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions."	1.38	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012)
" The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement."	1.37	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. ( Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011)
"Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis."	1.37	Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy. ( Matthai, WH; Patel, PJ; Untereker, WJ, 2011)
"Needle injury induces atherosclerotic plaque rupture with exposure of plaque material and formation of a thrombus that is larger, nearly occlusive and more stable as compared to that formed by application of ultrasounds."	1.37	Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. ( Gachet, C; Hechler, B, 2011)
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."	1.37	Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."	1.36	Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Only amlodipine was associated with clopidogrel poor-response."	1.36	The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."	1.36	Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
"The underlying disease was paroxysmal nocturnal hemoglobinuria (PNH), a stem cell defect characterized by episodes of complement-induced hemolysis and thromboembolic events."	1.36	[Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria]. ( Reinhart, WH, 2010)
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."	1.36	[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. ( Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."	1.35	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Myocardial infarction is common in patients with a history of coronary artery disease."	1.35	[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008)
"Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)."	1.35	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009)
" Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted."	1.35	Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. ( Endemann, S; Ernst, A; Gollapudi, RR; Levisay, JP; Price, MJ; Sawhney, NS; Schatz, RA; Stinis, CT; Teirstein, PS; Valencia, R, 2008)
"Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment."	1.34	Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine. ( Almsherqi, ZA; Deng, Y; McLachlan, CS; Mossop, P, 2007)
"Ticlopidine has a relative high rate of side-effects."	1.34	Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. ( Fukushima, K; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T; Okuno, T; Sakakibara, M; Shimizu, Y, 2007)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	1.34	Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
" Prasugrel is orally more potent and acts more rapidly than clopidogrel, allowing lower oral dosing despite of similar in vitro activity of the active metabolites."	1.34	[Prasugrel, a new thienopyridine]. ( Huber, K; Schrör, K, 2007)
"ticlopidine) treatment remained the sole predictor of TSO (OR: 5."	1.33	Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005)
" Clopidogrel was studied in two dosing regimens representing either a clinical pretreatment regimen (PTR) of 4."	1.33	Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. ( Brooks, JM; Crandall, DL; Hennan, JK; Leik, CE; Morgan, GA; Schaub, RG; Shaw, GD; Swillo, RE; Vlasuk, GP, 2006)
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."	1.32	Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)
" We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients."	1.32	Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. ( Alford, AB; Bell, CR; Cummings, CC; Gurbel, PA; Meister, AF; Serebruany, VL, 2003)
"Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis."	1.30	Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997)

Research

Studies (496)

Authors

Clinical Trials (105)

Trial Overview

Trial Outcomes

P2Y12 Reaction Unit (PRU)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (0.40)	18.7374
1990's	49 (9.88)	18.2507
2000's	229 (46.17)	29.6817
2010's	215 (43.35)	24.3611
2020's	1 (0.20)	2.80

Authors	Studies
Capodanno, D	3
Stefanini, GG	1
Vicenzi, M	1
Nikolaou, NI	1
Secemsky, EA	1
Yeh, RW	2
Kereiakes, DJ	4
Cutlip, DE	6
Steg, PG	14
Massaro, JM	2
Apruzzese, PK	1
Mauri, L	4
Felix, CM	1
Vlachojannis, GJ	1
IJsselmuiden, AJJ	1
Fam, JM	1
Smits, PC	1
Lansink, WJ	1
Diletti, R	1
Zijlstra, F	3
Regar, ES	1
Boersma, E	2
Onuma, Y	2
van Geuns, RJM	1
Zhou, Y	2
Wang, Y	1
Wu, Y	1
Huang, C	1
Yan, H	1
Zhu, W	1
Xu, W	1
Zhang, L	3
Zhu, J	2
Didier, R	1
Morice, MC	3
Barragan, P	7
Noryani, AAL	1
Noor, HA	1
Majwal, T	1
Hovasse, T	1
Castellant, P	1
Schneeberger, M	1
Maillard, L	1
Bressolette, E	1
Wojcik, J	1
Delarche, N	2
Blanchard, D	1
Jouve, B	1
Ormezzano, O	2
Paganelli, F	7
Levy, G	1
Sainsous, J	3
Carrie, D	3
Furber, A	1
Berlan, J	1
Darremont, O	1
Le Breton, H	1
Lyuycx-Bore, A	1
Gommeaux, A	1
Cassat, C	1
Kermarrec, A	1
Cazaux, P	2
Druelles, P	1
Dauphin, R	1
Armengaud, J	1
Dupouy, P	2
Champagnac, D	1
Ohlmann, P	1
Ben Amer, H	1
Kiss, RG	2
Ungi, I	1
Gilard, M	2
Jiang, M	1
You, JHS	1
Baber, U	8
Chandrasekhar, J	3
Sartori, S	5
Aquino, M	3
Kini, AS	3
Kapadia, S	2
Weintraub, W	2
Muhlestein, JB	3
Vogel, B	3
Faggioni, M	2
Farhan, S	3
Weiss, S	2
Strauss, C	2
Toma, C	2
DeFranco, A	2
Baker, BA	2
Keller, S	2
Effron, MB	3
Henry, TD	8
Rao, S	2
Pocock, S	4
Dangas, G	6
Mehran, R	13
Stuckey, TD	5
Kirtane, AJ	10
Brodie, BR	6
Witzenbichler, B	8
Litherland, C	2
Weisz, G	6
Rinaldi, MJ	6
Neumann, FJ	7
Metzger, DC	5
Cox, DA	4
Duffy, PL	4
Mazzaferri, EL	4
Gurbel, PA	9
Généreux, P	5
Ben-Yehuda, O	3
Simonton, CA	2
Stone, GW	16
Harada, Y	1
Michel, J	1
Lohaus, R	1
Mayer, K	3
Emmer, R	1
Lahmann, AL	1
Colleran, R	1
Giacoppo, D	1
Wolk, A	1
Ten Berg, JM	8
Han, Y	1
Adriaenssens, T	1
Tölg, R	1
Seyfarth, M	2
Maeng, M	2
Zrenner, B	1
Jacobshagen, C	1
Wöhrle, J	1
Kufner, S	1
Morath, T	6
Ibrahim, T	1
Bernlochner, I	4
Fischer, M	1
Schunkert, H	3
Laugwitz, KL	4
Mehilli, J	5
Byrne, RA	4
Kastrati, A	9
Schulz-Schüpke, S	1
Zafar, MU	1
Smith, DA	1
Contreras, J	1
Rey-Mendoza, J	1
Linares-Koloffon, CA	1
Escolar, G	1
Fuster, V	1
Badimon, JJ	1
Piccolo, R	2
Feres, F	2
Abizaid, A	3
Hong, MK	7
Kim, HS	3
Colombo, A	17
Bhatt, DL	10
Palmerini, T	3
Windecker, S	4
Valgimigli, M	7
Bossard, M	1
Granger, CB	2
Tanguay, JF	1
Montalescot, G	8
Faxon, DP	2
Jolly, SS	1
Widimsky, P	3
Niemela, K	1
Natarajan, MK	1
Gao, P	1
Fox, KAA	1
Yusuf, S	2
Mehta, SR	2
Sorrentino, S	1
Ge, Z	1
Almalla, M	1
Schröder, J	1
Hennings, V	1
Marx, N	1
Hoffmann, R	1
Rinfret, S	1
Rodés-Cabau, J	2
Bagur, R	1
Déry, JP	2
Dorais, M	1
Larose, E	2
Barbeau, G	1
Gleeton, O	2
Nguyen, CM	2
Noël, B	2
Proulx, G	2
Roy, L	2
Taillon, I	1
De Larochellière, R	2
Bertrand, OF	2
Echavarría-Pinto, M	1
Lopes, R	1
Gorgadze, T	1
Gonzalo, N	1
Hernández, R	3
Jiménez-Quevedo, P	4
Alfonso, F	5
Bañuelos, C	3
Nuñez-Gil, IJ	1
Ibañez, B	1
Fernández, C	2
Fernandez-Ortiz, A	3
García, E	1
Macaya, C	5
Escaned, J	3
Prech, M	1
Janus, M	1
Lukawski, K	1
Lesiak, M	1
Storey, RF	6
Park, J	1
Shin, DH	2
Kim, BK	2
Her, AY	2
Kim, YH	4
Choi, HH	1
Kim, JS	3
Ko, YG	2
Choi, D	2
Jang, Y	2
Berglund, U	1
Nilsson, L	1
Janzon, M	1
Cano, P	1
Consuegra-Sánchez, L	1
Conesa, P	1
Torres-Moreno, D	1
Jaulent, L	1
Dau, D	1
Picó, F	1
Villegas, M	1
Tantry, US	7
Kunadian, V	1
James, SK	3
Wojdyla, DM	3
Zorkun, C	1
Wu, J	1
Katus, H	2
Emanuelsson, H	5
Horrow, J	1
Maya, J	1
Wallentin, L	6
Harrington, RA	11
Gibson, CM	11
Liang, ZY	1
Han, YL	2
Zhang, XL	1
Li, Y	4
Yan, CH	1
Kang, J	1
Katus, HA	3
Mahaffey, KW	9
Meier, B	3
Lewis, BS	2
Maurer, G	2
Cuisset, T	6
Grosdidier, C	1
Loundou, AD	1
Quilici, J	4
Loosveld, M	1
Camoin, L	2
Pankert, M	2
Beguin, S	1
Lambert, M	1
Morange, PE	2
Bonnet, JL	5
Alessi, MC	3
Suh, SY	1
Kang, WC	1
Oh, PC	1
Choi, H	1
Moon, CI	1
Lee, K	1
Han, SH	1
Ahn, T	1
Choi, IS	1
Shin, EK	1
Park, KW	1
Kang, SH	1
Park, JJ	1
Yang, HM	1
Kang, HJ	1
Koo, BK	2
Park, BE	1
Cha, KS	1
Rhew, JY	1
Jeon, HK	1
Shin, ES	1
Oh, JH	1
Jeong, MH	5
Kim, S	1
Hwang, KK	1
Yoon, JH	2
Lee, SY	1
Park, TH	1
Moon, KW	1
Kwon, HM	1
Chae, IH	2
Mao, L	1
Jian, C	1
Changzhi, L	1
Dan, H	1
Suihua, H	1
Wenyi, T	1
Wei, W	1
Chen, Y	1
Zhang, Y	2
Tang, Y	1
Huang, X	1
Xie, Y	1
Musumeci, G	2
Limbruno, U	2
Viviani Anselmi, C	1
Briguori, C	2
Roncarati, R	1
Papa, L	1
Visconti, G	1
Focaccio, A	1
De Micco, F	1
Latronico, MV	1
Pagnotta, P	1
Condorelli, G	1
Tebaldi, M	2
Borghesi, M	1
Vranckx, P	3
Campo, G	4
Tumscitz, C	1
Cangiano, E	1
Minarelli, M	1
Scalone, A	1
Cavazza, C	1
Marchesini, J	1
Parrinello, G	2
Ferreiro, JL	1
Sánchez-Salado, JC	1
Gracida, M	1
Marcano, AL	1
Roura, G	1
Ariza, A	1
Gómez-Lara, J	1
Lorente, V	1
Romaguera, R	1
Homs, S	1
Sánchez-Elvira, G	1
Teruel, L	1
Rivera, K	1
Sosa, SG	1
Gómez-Hospital, JA	1
Angiolillo, DJ	12
Cequier, A	2
Deharo, P	1
Bonnet, G	1
Verdier, V	1
Morange, P	1
Waks, JW	1
Sabatine, MS	3
Cannon, CP	4
Morrow, DA	2
Wiviott, SD	2
Giugliano, RP	1
Sloan, S	1
Scirica, BM	1
Hansson, EC	1
Rexius, H	1
Dellborg, M	2
Albertsson, P	1
Jeppsson, A	1
Silber, S	1
Belardi, JA	1
Liu, M	1
Brar, S	1
Rothman, M	1
Camenzind, E	1
Wijns, W	3
Rademaker-Havinga, T	1
Ordoubadi, FF	1
Suttorp, MJ	3
Al Kurdi, M	1
Sabouret, P	2
Taiel-Sartral, M	1
Murray, AM	1
Keville, N	1
Gray, S	1
Schulz, S	5
Braun, S	4
Hausleiter, J	3
Massberg, S	4
Sibbing, D	8
Kazi, DS	1
Garber, AM	1
Shah, RU	1
Dudley, RA	1
Mell, MW	1
Rhee, C	1
Moshkevich, S	1
Boothroyd, DB	1
Owens, DK	1
Hlatky, MA	1
Ho, HH	1
Er Ching, M	1
Ong, PJ	1
Ooi, YW	1
Rangé, G	2
Yayehd, K	1
Belle, L	2
Thuaire, C	1
Richard, P	1
Barbou, F	1
Köning, R	1
Chassaing, S	1
Teiger, E	1
Berthier, R	1
Decomis, MP	1
Claudel, JP	1
Brunel, P	1
De Poli, F	1
Beygui, F	3
Albert, F	1
Collet, JP	6
Davlouros, P	2
Gkizas, V	1
Deftereos, S	1
Giannopoulos, G	1
Alexopoulos, D	2
Ayers, J	1
Mandell, R	1
Sanghvi, K	1
Aboujaoude, R	1
Hsi, DH	1
Roguin, A	1
Musallam, A	1
Liang, J	1
Wang, Z	1
Shi, D	1
Liu, Y	2
Zhao, Y	1
Han, H	1
Liu, W	1
Yang, L	1
Legrand, V	1
Chenu, P	1
Vrolix, M	1
Martinez, C	1
Dens, J	1
Gach, O	1
Boland, J	1
Claeys, MJ	1
Magne, J	1
Barbato, E	1
Parekh, P	1
Agrawal, N	1
Vasavada, A	1
Vinchurkar, M	1
Thim, T	1
Johansen, MB	1
Chisholm, GE	1
Schmidt, M	1
Kaltoft, A	1
Sørensen, HT	1
Thuesen, L	2
Kristensen, SD	3
Bøtker, HE	1
Krusell, LR	1
Lassen, JF	1
Thayssen, P	1
Jensen, LO	1
Tilsted, HH	1
Orban, M	2
Hadamitzky, M	1
Hoppmann, P	1
Tiroch, K	1
Ramaiola, I	1
Padró, T	1
Peña, E	1
Juan-Babot, O	1
Cubedo, J	1
Martin-Yuste, V	1
Sabate, M	7
Badimon, L	1
Siller-Matula, JM	1
Trenk, D	2
Schrör, K	3
Gawaz, M	6
Huber, K	4
Calabrò, P	1
Piscione, F	2
De Servi, S	2
Cattaneo, M	3
Maffeo, D	1
Toso, A	1
Bartorelli, A	1
Palmieri, C	1
De Carlo, M	2
Barozzi, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients[NCT01823510]	Phase 4	20 participants (Actual)	Interventional	2013-07-31	Completed
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]	Phase 3	25,086 participants (Actual)	Interventional	2006-06-30	Completed
Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial[NCT01134679]		300 participants (Actual)	Interventional	2009-06-30	Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615]		4,500 participants (Actual)	Observational	2015-01-31	Completed
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038]		2,000 participants (Anticipated)	Observational [Patient Registry]	2015-07-31	Recruiting
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]	Phase 4	3,750 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]	Phase 4	1,700 participants (Anticipated)	Interventional	2006-12-31	Completed
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902]		25 participants (Actual)	Observational [Patient Registry]	2022-02-03	Completed
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]		2,349 participants (Actual)	Observational	2008-08-31	Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]		1,492 participants (Anticipated)	Observational [Patient Registry]	2019-08-01	Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]		1,516 participants (Actual)	Interventional	2008-07-31	Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]		100 participants (Actual)	Interventional	2009-03-31	Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]	Phase 4	2,292 participants (Actual)	Interventional	2008-04-30	Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]	Phase 4	8,709 participants (Actual)	Interventional	2007-06-30	Completed
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753]		1,001 participants (Actual)	Observational	2008-02-29	Completed
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003]	Phase 4	2,272 participants (Actual)	Interventional	2010-04-30	Completed
Platelet Function in Resuscitated Patients-2[NCT03445546]		25 participants (Actual)	Observational	2016-05-01	Completed
A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310]	Phase 3	300 participants (Actual)	Interventional	2005-07-31	Completed
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions[NCT00402272]	Phase 4	2,700 participants (Actual)	Interventional	2006-11-30	Completed
SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479]	Phase 3	1,002 participants (Actual)	Interventional	2005-06-30	Completed
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions[NCT00496938]	Phase 4	1,600 participants (Actual)	Interventional	2007-07-31	Completed
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study[NCT00631228]		1,000 participants (Actual)	Observational	2008-06-30	Completed
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study[NCT00676520]		8,053 participants (Actual)	Observational	2008-07-31	Completed
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00307047]	Phase 3	3,687 participants (Actual)	Interventional	2006-08-31	Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]	Phase 3	11,145 participants (Actual)	Interventional	2010-09-30	Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052]	Phase 4	634 participants (Anticipated)	Interventional	2021-07-02	Recruiting
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]		8,575 participants (Actual)	Observational	2008-01-31	Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]		5,031 participants (Actual)	Observational	2009-06-30	Completed
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281]		1,079 participants (Actual)	Interventional	2010-10-31	Completed
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]	Phase 4	25,682 participants (Actual)	Interventional	2009-10-31	Completed
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591]	Phase 3	13,619 participants (Actual)	Interventional	2004-11-30	Completed
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953]	Phase 4	190 participants (Actual)	Interventional	2010-01-31	Active, not recruiting
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940]	Phase 4	310 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878]	Phase 4	130 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424]		100 participants (Anticipated)	Observational [Patient Registry]	2016-05-31	Recruiting
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463]	Phase 4	263 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725]	Phase 3	0 participants (Actual)	Interventional		Withdrawn (stopped due to Study was not initiated, change in clinical development)
Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775]	Phase 4	4,000 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832]	Phase 4	951 participants (Anticipated)	Interventional	2011-07-31	Active, not recruiting
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]		88 participants (Actual)	Observational	2018-01-01	Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]		1,800 participants (Anticipated)	Observational [Patient Registry]	2018-11-21	Not yet recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139]	Phase 2/Phase 3	102 participants (Actual)	Interventional	2011-09-30	Completed
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]		889 participants (Actual)	Interventional	2013-06-30	Terminated (stopped due to Ethics Committe decision)
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2010-08-31	Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]		280 participants (Actual)	Observational	2014-06-30	Completed
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Not yet recruiting
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241]	Phase 3	280 participants (Anticipated)	Interventional	2020-02-01	Recruiting
Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757]	Phase 3	200 participants (Anticipated)	Interventional	2019-04-01	Not yet recruiting
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]	Phase 4	40 participants (Actual)	Interventional	2020-06-23	Completed
Chinese People's Liberation Army General Hospital[NCT02798874]		240 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790]	Phase 4	600 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544]	Phase 4	187 participants (Actual)	Interventional	2009-04-30	Completed
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]	Phase 3	3,602 participants (Actual)	Interventional	2005-03-31	Completed
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912]		2,016 participants (Actual)	Observational [Patient Registry]	2008-07-31	Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]	Phase 4	9,006 participants (Actual)	Interventional	2015-07-31	Completed
Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI[NCT01360437]	Phase 3	44 participants (Actual)	Interventional	2011-05-31	Completed
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411]	Phase 4	2,500 participants (Actual)	Interventional	2009-01-31	Completed
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785]		90 participants (Actual)	Observational	2017-03-27	Completed
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131]	Phase 4	1,856 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147]		400 participants (Actual)	Observational	2013-08-31	Completed
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335]	Phase 1	30 participants (Actual)	Interventional	2010-11-30	Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]		120 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]	Phase 4	150 participants (Actual)	Interventional	2007-09-30	Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]	Phase 4	190 participants (Anticipated)	Interventional	2010-06-30	Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]	Phase 4	200 participants (Anticipated)	Interventional	2005-03-31	Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]	Phase 4	20 participants (Actual)	Interventional	2009-06-30	Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]	Phase 4	80 participants (Actual)	Interventional	2008-11-30	Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]	Phase 3	200 participants (Actual)	Interventional	2005-06-30	Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]	Phase 4	20 participants (Actual)	Interventional	2016-06-26	Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]		100 participants (Anticipated)	Observational	2015-09-30	Not yet recruiting
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]		159 participants (Actual)	Interventional	2006-05-31	Completed
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]	Phase 3	30 participants (Anticipated)	Interventional	2009-04-30	Recruiting
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451]	Phase 4	1,721 participants (Actual)	Interventional	2006-07-31	Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330]	Phase 3	180 participants (Anticipated)	Interventional	2013-01-31	Recruiting
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771]	Phase 4	44 participants (Anticipated)	Interventional	2007-11-30	Not yet recruiting
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004]	Phase 4	60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]		179 participants (Actual)	Interventional	2003-01-31	Completed
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654]	Phase 3	60 participants (Actual)	Interventional	2010-09-30	Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]	Phase 4	30 participants (Anticipated)	Interventional	2007-11-30	Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]	Phase 4	77 participants (Anticipated)	Interventional	2006-08-31	Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]		60 participants (Actual)	Interventional	2008-05-31	Completed
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]		33 participants (Actual)	Observational	2014-12-31	Completed
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561]		44 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]	Phase 4	60 participants (Actual)	Interventional	2012-04-30	Completed
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]		31 participants (Actual)	Interventional	2014-09-30	Completed
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]	Phase 4	200 participants (Actual)	Interventional	2006-01-31	Completed
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175]		1,960 participants (Actual)	Interventional	2013-01-16	Terminated (stopped due to Slow enrollment)
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]	Phase 4	50 participants (Actual)	Interventional	2017-02-16	Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]		0 participants (Actual)	Observational	2010-11-30	Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]		8 participants (Actual)	Interventional	2013-09-30	Completed
Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475]	Phase 3	442 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934]	Phase 4	64 participants (Anticipated)	Interventional	2018-09-26	Recruiting
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720]	Phase 3	3,400 participants (Anticipated)	Interventional	2020-10-15	Recruiting
French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022]		300 participants (Anticipated)	Observational [Patient Registry]	2022-06-15	Recruiting
Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809]	Phase 4	240 participants (Actual)	Interventional	2006-08-31	Completed
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]		300 participants	Interventional	2001-04-30	Active, not recruiting
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401]	Phase 3	2,399 participants (Actual)	Interventional	1996-07-31	Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]	Phase 4	2,022 participants (Actual)	Interventional	2003-03-31	Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]	Phase 4	800 participants (Actual)	Interventional	2003-06-30	Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]	Phase 4	60 participants (Actual)	Interventional	2004-10-31	Completed
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309]		30 participants (Anticipated)	Interventional	2006-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow (NCT01823510)
Timeframe: up to 7 days

Platelet Reactivity

Intervention	percentage of baseline PRU (Mean)
	2 hour post-loading dose	6 hour post-loading dose	5-7 days of maintenance dosing
Clopidogrel + Aspirin	77.8	66.8	62.7
Ticagrelor + Aspirin	14.8	8.2	14.5

Platelet reactivity by Multiplate Analyzer (NCT01823510)
Timeframe: up to 7 days

Platelet Reactivity Index (PRI)

Intervention	percentage of baseline Unit (Mean)
	2 hour post-loading dose	6 hour post-loading dose	5-7 days of maintenance dosing
Clopidogrel + Aspirin	54.5	43.6	45.5
Ticagrelor + Aspirin	20.5	20.6	24.2

Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay. (NCT01823510)
Timeframe: up to 7 days

Thrombus Formation

Intervention	percentage of baseline PRI (Mean)
	2 hour post-loading dose	6 hour post-loading dose	5-7 days of maintenance dosing
Clopidogrel + Aspirin	85.8	82.5	68.4
Ticagrelor + Aspirin	21.8	17.8	17.2

Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis). (NCT01823510)
Timeframe: up to 7 days

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

Intervention	percentage of baseline size (Mean)
	2 hour post loading dose	6 hours post loading dose	5-7 days of maintenance dose
Clopidogrel + Aspirin	84.4	79.8	82.6
Ticagrelor + Aspirin	66.9	59.9	68.9

Intervention	participants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose	267
Clopidogrel 300/75/75 mg + ASA High Dose	290
Clopidogrel 600/150/75 mg + ASA Low Dose	282
Clopidogrel 600/150/75 mg + ASA High Dose	240

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel + ASA High Dose	527	211	251	65
Clopidogrel + ASA Low Dose	546	231	260	55

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

Occurrence of Major Bleeding - ASA Dose Level Comparison

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA	557	222	274	61
Clopidogrel 600/150/75 mg + ASA	522	226	237	59

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA	392	132	225	35
Clopidogrel 600/150/75 mg + ASA	330	130	172	28

Intervention	participants (Number)
	Major bleeding	- Severe bleeding	- Major but not severe bleeding
Clopidogrel + ASA High Dose	282	216	73
Clopidogrel + ASA Low Dose	285	215	74

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

Intervention	participants (Number)
	Major bleeding	- Severe bleeding	- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA	255	195	65
Clopidogrel 600/150/75 mg + ASA	313	236	83

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Intervention	participants (Number)
	Stent trombosis	- Definite	- Probable
Clopidogrel 300/75/75 mg + ASA	200	111	89
Clopidogrel 600/150/75 mg + ASA	135	58	77

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Intervention	Participants (Number)
TICAGRELOR	901
CLOPIDOGREL	1065

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Intervention	Participants (Number)
TICAGRELOR	1290
CLOPIDOGREL	1456

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Intervention	Participants (Number)
TICAGRELOR	569
CLOPIDOGREL	668

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Major Bleeding Event

Intervention	Participants (Number)
TICAGRELOR	864
CLOPIDOGREL	1014

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	961
CLOPIDOGREL	929

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Intervention	Participants (Number)
TICAGRELOR	619
CLOPIDOGREL	654

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Death From Any Cause

Intervention	Participants (Number)
TICAGRELOR	329
CLOPIDOGREL	341

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Death From Vascular Causes

Intervention	Participants (Number)
TICAGRELOR	399
CLOPIDOGREL	506

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Major or Minor Bleeding

Intervention	Participants (Number)
TICAGRELOR	353
CLOPIDOGREL	442

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With MI Event

Intervention	Participants (Number)
TICAGRELOR	1339
CLOPIDOGREL	1215

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	504
CLOPIDOGREL	593

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Non-procedural Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	362
CLOPIDOGREL	306

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Stroke

Intervention	Participants (Number)
TICAGRELOR	235
CLOPIDOGREL	180

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Intervention	Participants (Number)
TICAGRELOR	125
CLOPIDOGREL	106

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Intervention	Participants (Number)
TICAGRELOR	21
CLOPIDOGREL	16

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

Death

Major Adverse Cardiac Event (MACE)

Intervention	Participants (Number)
TICAGRELOR	84
CLOPIDOGREL	51

Intervention	percentage of participants (Number)
Cardiac Death or Target Vessel MI	4.2

Intervention	percentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)	0.9

Intervention	percentage of participants (Number)
Primary Enrollment Group	1.3

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Stent Thrombosis (ST)

Intervention	percentage of participants (Number)
Primary Enrollment Group	5.5

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Target Lesion Failure (TLF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	0.1

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Target Vessel Failure (TVF)

Intervention	percentage of participants (Number)
Primary Enrollment Group	4.7

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Target Vessel MI

Intervention	percentage of participants (Number)
Primary Enrollment Group	6.3

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

In-stent Late Lumen Loss (LLL)

Intervention	percentage of eligible participants (Number)
Primary Enrollment Group	1.4

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Intervention	mm (Mean)
Zotarolimus Eluting Stent	0.13

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

In-Stent Percent Diameter Stenosis

Intervention	percentage of participants with TLF (Number)
Zotarolims Eluting Stent	4.0

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

Target Lesion Failure

Intervention	Percentage diameter stenosis (Mean)
1. Resolute - 12-13 Months	21.65
2. XIENCE V - 12-13 Months	19.76

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Intervention	percentage of participants (Number)
1. Resolute - 12-13 Months	8.2
2. XIENCE V - 12-13 Months	8.3

Intervention	participants (Number)
E-ZES	61
C-SES	75

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects

Intervention	participants (Number)
	Total death and large non-fatal myocardial infarct	Total death and non-fatal myocardial infarctions	Cardiac death and large non-fatal MI	Cardiac death and non-fatal MI	Target lesion revascularization	Stroke	Bleeding events
C-SES	255	360	174	282	156	72	184
E-ZES	225	331	157	265	249	77	201

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects

Intervention	Percentage of participants (Number)
Placebo Arm	1.8
Thienopyridine Therapy	2.0
Surveillance Arm	4.8

"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects

Intervention	percentage of participants (Number)
Placebo Arm	1.0
Thienopyridine Therapy	0.5
Surveillance Arm	2.4

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

% Volume Obstruction (% VO)

Intervention	Percentage of participants (Number)
Placebo Arm	4.3
Thienopyridine Therapy	4.8
Surveillance Arm	16.9

Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days

Acute Success: Clinical Device

Intervention	percent of volume obstruction (Mean)
XIENCE V® EECSS	6.91
TAXUS® EXPRESS2™ ECSS	11.21

Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Acute Success: Clinical Procedure

Intervention	percentage of participants (Number)
XIENCE V® EECSS	98.3
TAXUS® EXPRESS2™ ECSS	98.7

Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Distal Late Loss

Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days

In-segment % Angiographic Binary Restenosis (% ABR) Rate

Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days

In-segment % Diameter Stenosis (% DS)

Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days

In-stent % Angiographic Binary Restenosis (% ABR) Rate

Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days

In-stent % Diameter Stenosis (% DS)

In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days

In-stent Late Loss

In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year

Ischemia Driven Major Adverse Cardiac Event (MACE)

Ischemia Driven Major Adverse Cardiac Event(MACE)

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years

Ischemia Driven Target Lesion Revascularization (ID-TLR)

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year

Ischemia Driven Target Vessel Revascularization (ID-TVR)

Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days

Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection

"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days

Primary Endpoint: In-segment Late Loss (LL)

In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days

Proximal Late Loss

Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days

Target Vessel Failure (TVF)

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Clinical Device Success

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death and Any Myocardial Infarction (MI)

Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 1 year

Dual Antiplatelet Medication Usage

Dual Antiplatelet Therapy Non-compliance Through 1 Year

Defined as patients who had at least 1 day without using either aspirin or thienopyridine from 1 to 407 days post index procedure. (NCT00676520)
Timeframe: 1 year

Major Bleeding Complications

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 1 year

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

Procedural Success

Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)

SAQ (Seattle Angina Questionaire)

Stent Thrombosis (Definite and Probable) Rate as Defined by ARC (Academic Research Constortium).

"ARC Defines Stent Thrombosis in the following way:~Definite Stent Thrombosis: Angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region AND at least ONE of the following, additional criteria:~Acute ischemic symptoms Ischemic ECG changes Elevated cardiac biomarkers~Probable Stent Thrombosis: Any unexplained death within 30 days of stent implantation or any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause~Possible Stent Thrombosis Any unexplained death beyond 30 days~For further information on ARC definitions, please refer to the following website: http://circ.ahajournals.org/content/115/17/2344.full#sec-1" (NCT00676520)
Timeframe: up to 1 year

Acute Success (Clinical Device)

Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met. (NCT00307047)
Timeframe: Acute: At time of index procedure

Acute Success (Clinical Procedure)

Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success. (NCT00307047)
Timeframe: Acute: At time of index procedure

All Cause Mortality

All MI

All Myocardial Infarction (MI)

Cardiac Death or Target Vessel MI Rate

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-30 days

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 1 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 180 days

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 2 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 270 days

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 3 years

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 30 days

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Lesion Failure (TLF)

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Lesion Revascularization (TLR)

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 180 days

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 2 years

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 270 days

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 3 years

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 30 days

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Ischemia Driven Target Vessel Revascularization (TVR)

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-1123 days

Protocol Defined Stent Thrombosis Rate

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days

Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days

Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding

Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days

Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis

Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year

Stent Arm - Ischemic Target Lesion Revascularization

Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year

Stent Arm - Segment Binary Angiographic Restenosis

Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

Target Vessel Revascularization (TVR)

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Major Adverse Cardiovascular Events (MACCE)

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

Percent Stent Coverage

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

Intervention	units on the SAQ scale (Mean)
Physical Limitations	76.0
Angina Stability	54.3
Angina Frequency	90.7
Treatment Satisfaction	92.2
Perception of Disease/Quality of Life	78.0

Intervention	units on the SAQ scale (Mean)
Physical Limitations	75.8
Angina Stability	57.3
Angina Frequency	90.1
Treatment Satisfaction	91.4
Perception of Disease/Quality of Life	76.8

Intervention	units on the SAQ scale (Mean)
Physical Limitations	70.0
Angina Stability	42.0
Angina Frequency	73.1
Treatment Satisfaction	98.1
Perception of Disease/Quality of Life	55.3

Intervention	participants (Number)
	GUSTO severe/life threatening	GUSTO moderate	GUSTO severe or moderate	TIMI major	TIMI minor	TIMI major or minor	Any blood transfusion
Cangrelor Treatment Arm	9	22	31	5	9	14	25
Clopidogrel Treatment Arm	6	13	19	5	3	8	16

Intervention	participants (Number)
	Stent Thrombosis	Death	MI (myocardial infarction)	IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm	46	18	207	28
Clopidogrel Treatment Arm	74	18	255	38

Intervention	Participants (Number)
	All ACS (Through 30 days)	All ACS (Through 90 days)
Clopidogrel	502	573
Prasugrel	389	462

Intervention	Participants (Number)
	UA/NSTEMI (n=5044, n=5030)	STEMI (n=1769, n=1765)	All ACS (n=6813, n=6795)
Clopidogrel	565	216	781
Prasugrel	469	174	643

Intervention	Participants (Number)
	TIMI Major or Minor Bleeding	TIMI Major Bleeding	TIMI Major Bleeding - Life-threatening (LT)	LT - Fatal	LT - Symptomatic intracranial hemorrage (ICH)	LT - Requiring inotropes	LT - Requiring surgical intervention	LT - Requiring transfusion (>=4 units)	TIMI Minor Bleeding
Clopidogrel	231	111	56	5	17	8	19	30	125
Prasugrel	303	146	85	21	19	21	19	45	164

Intervention	Participants (Count of Participants)
Pharmacology Arm - Bivalirudin	379
Pharmacology Arm - Unfractionated Heparin	377

Intervention	Participants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent	181
Stent Arm - Bare Metal Stent	59

Intervention	US dollars (Mean)
Oral Sirolimus + Bare Metal Stent	5483
Drug Eluting Stents	7658.2

Intervention	participants (Number)
	MACCE	Death	Acute Myocardial Infarction	Stroke
Drug Eluting Stents	15	7	9	1
Oral Sirolimus + Bare Metal Stent	9	3	6	0

Intervention	Participants (Count of Participants)
	85% up to 90% stent coverage	90% up to 95% stent coverage	95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent	0	1	0
Non-diabetic Patients Receiving the Resolute Stent	1	3	1